Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Synchrony Financial (SYF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Synchrony Financial — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Synchrony Financial trades at $72.44 (market cap $24.37B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Synchrony Financial pays a 1.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SYF | |
|---|---|---|
Market Cap | $39.89B | $24.37B |
Sector | Health | Financials |
52-Week High | $491.22 | $88.47 |
52-Week Low | $278.09 | $63.78 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Synchrony Financial (SYF) trades at $72.44, up 1.22% with strong fundamental metrics including a low P/E of 7.5 and robust ROE of 22.98%. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results expected July 21. Technical indicators show bearish momentum despite neutral oscillators, with key support at $69 and resistance at $73. Recent corporate developments include executive leadership changes and expansion of CareCredit partnerships.
SYF presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. The stock offers 19% upside to consensus price target of $86, supported by strong analyst sentiment (62.5% buy ratings). Key risks include economic sensitivity to consumer credit and inflationary pressures. The upcoming Q2 earnings report will be crucial for confirming the company's growth trajectory amid current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
